Vitex (Chasteberry) Supplements: Which Extract, What Dose, and What th – Agape Nutrition
Left Continue shopping
Your Order

You have no items in your cart

Vitex chasteberry sprig and amber bottle beside 20 mg and 225 mg cards marked not the same extract

Vitex (Chasteberry) Supplements: Which Extract, What Dose, and What the Trials Show

If you have stood in front of a shelf of vitex bottles, you have seen the problem. One label says 225 mg. Another says 400 mg. The research that made vitex well known used 20 mg of one specific extract, once a day, for three cycles. Those numbers describe different things, and treating them as interchangeable is the most common mistake in the category. This guide separates what was tested from what was printed on a label, names the two extracts behind most of the clinical evidence, grades the evidence symptom by symptom, and shows you how to read any bottle before you spend money.

Table of Contents

What vitex is

Vitex agnus-castus is a shrub native to the Mediterranean and Central Asia. Its dried fruit is sold as chasteberry, chaste tree berry, or monk's pepper. It has a long history of use for cycle-related complaints, and modern supplements sell it as either a dried fruit powder or a standardized extract.

The compounds behind the interest

The fruit contains iridoids such as agnuside and aucubin, along with diterpenes and flavonoids. Most labels standardize to agnusides or casticin. That marker lets you compare two products on one chemical, but it does not tell you which extract you are holding. A standardization percentage is not the same thing as the dose used in research.

How it is proposed to work

The leading explanation involves dopamine. Vitex is proposed to act on dopamine D2 receptors in the anterior pituitary, which may lower prolactin release. A 2003 review by Wuttke and colleagues described dopaminergic, opioidergic, and other activity, much of it from laboratory work. A 2023 review by Puglia and colleagues found some evidence in selected patients with mild hyperprolactinemia, with no large randomized trials.

Treat this as proposed, not established. The mechanism is a hypothesis with supporting lab data, not a guarantee about what a bottle will do. It does tell you something practical: a plant with dopaminergic activity belongs on your pharmacist's interaction list, not in the same mental category as a multivitamin.

Why the milligram number is not the dose that was tested

This is the part most articles skip. Two bottles can both say "vitex" and deliver very different things.

The two extracts the trials used

Two named extracts carry almost all of the clinical evidence:

  • Ze 440. A dry extract of the fruit, 20 mg per tablet, made with 60% ethanol at a drug-to-extract ratio of 6 to 12 to 1, equivalent to about 180 mg of dried fruit (Schellenberg 2012; Erkert 2026). Tested at one tablet daily for three cycles in PMS trials (Schellenberg 2001 and 2012; Berger 2000).
  • BNO 1095. A separate standardized dry extract, tested as one tablet once daily for three cycles in a trial in Chinese women with moderate to severe PMS, reported in two papers (Ma 2010).

Those two names are what to look for. Everything else in the category is a different extract until its label says otherwise, even when the plant and the marker compound match.

Five things to check on any label

  1. Extract identity. Is there a trade name or extract code, or just "vitex extract"?
  2. Drug-to-extract ratio (DER). A 6 to 12 to 1 ratio means 6 to 12 parts dried fruit to 1 part finished extract.
  3. Extraction solvent. Water, ethanol, or a mix pulls out different compounds.
  4. Standardization marker. Agnusides, casticin, or a percentage of either.
  5. Milligrams per capsule and capsules per day. Multiply them to get your daily extract intake.

When a label leaves all of this out, you cannot compare it with anything. That is the practical cost of a vague supplement facts panel.

Here is how that plays out in practice. Bottle A lists "vitex fruit extract 225 mg, standardized to 0.5% agnusides, 1 capsule twice daily." Bottle B lists "Ze 440, 20 mg, 1 tablet daily." Bottle A gives you 450 mg of an unnamed extract per day. Bottle B gives you the exact preparation used in the three randomized trials cited here. Bottle A may be a perfectly good product. It is not the product the trials tested, and no one can tell you what 450 mg of it should do.

Label decoder contrasting 20 mg Ze 440 chasteberry extract with a 225 mg extract standardized to 0.5% agnusides.
A 225 mg extract is not a stronger version of a 20 mg studied extract. The extract identity is the difference.

Why a bigger number is not a bigger effect

Schellenberg 2012 randomized 162 women to placebo or 8, 20, or 30 mg of Ze 440 for three cycles. The 20 mg dose beat placebo and beat 8 mg. The 30 mg dose was no better than 20 mg. More was not more, even within the same extract.

That is the cleanest argument against shopping by milligram count. A 225 mg chaste tree capsule is not a stronger version of a 20 mg tablet. It is a different product with a different specification, and the label is the only place that difference shows up.

At Agape Nutrition we stock three vitex products, including a DIM and vitex combination, and none of them is Ze 440 or BNO 1095. That is not a reason to avoid them. It is a reason to read their labels carefully and set expectations from the evidence rather than from the milligrams.

The PMS evidence, graded

PMS is where vitex has the most data, and where those data are most often oversold. The honest grade is moderate: the direction is consistent, the size of the effect is uncertain.

What the meta-analyses found

Csupor 2019 screened 21 trials and could use only 3 double-blind, placebo-controlled trials covering 520 women. In those trials, women taking vitex were 2.57 times more likely to have a symptom response, with a 95% confidence interval of 1.52 to 4.35. The review also found that most published trials could not be included because the extract was poorly described. The same review that found a benefit found most of the literature unusable.

Verkaik 2017 pooled 14 trials and found a large effect, a Hedges g of -1.21. But heterogeneity was 91%, risk of bias was high, and publication bias was possible. The authors called the pooled result exploratory. A pooled effect that large, built from trials that weak, is more likely to overstate the truth than to understate it.

A 2017 systematic review by Cerqueira and colleagues paints a similar picture. It found 8 randomized trials across 3 different preparations, and all 8 reported positive results for PMS or PMDD. The catch is in the details: definitions, outcome measures, and preparations all varied. A pile of positive trials can still produce a cautious overall grade when no two trials measure the same thing the same way.

Vitex evidence ladder ranking PMS strongest, then cyclic breast pain, PMDD, cycle and fertility, then menopause.
The evidence is strongest for PMS and cyclic breast pain, and weakest for menopause and fertility.

The trials behind the numbers

  • Schellenberg 2001. 170 women evaluated, Ze 440, one tablet daily for three cycles. The response rate was 52% on active treatment versus 24% on placebo (P<0.001). Seven mild adverse events occurred, none leading to discontinuation.
  • Berger 2000. 50 patients took 20 mg daily for three cycles. Moos Menstrual Distress Questionnaire scores fell 42.5% (P<0.001), 20 of 43 completers were responders, and prolactin stayed within the normal range.
  • Ma 2010. The trial enrolled 67 women with moderate to severe PMS. PMS diary scores fell from 29.38 to 4.28 with BNO 1095, versus 28.76 to 11.79 with placebo. A companion paper on the same trial reported that all 17 tracked symptoms improved more than placebo except lower abdominal cramping.

What moderate means for you

It means the trials studied women with PMS and measured symptom scores, and most of those trials found improvement. It does not mean every woman responds. In the best single trial, about half did. A fair trial is three cycles of a product whose extract you can actually identify. If you want the broader picture on nutrients and lifestyle support for PMS, our guide to PMS supplements covers that ground.

How to read an evidence grade

Four things move a grade up or down, and they are worth knowing before you trust any supplement claim:

  1. Extract identity. A trial only tells you about the preparation it used. If the paper does not name the extract, the result cannot guide your decision.
  2. Blinding and size. Double-blind, placebo-controlled trials with a few hundred women count for more than open-label studies with forty.
  3. Consistency. When trials disagree wildly, the average is less trustworthy. That is what a heterogeneity score of 91% is warning you about.
  4. Outcome measure. A validated symptom diary is stronger than a general impression of "feeling better."

PMS scores well on direction and poorly on precision. That combination is exactly what moderate means.

Cyclic breast pain: the strongest secondary signal

Cyclic breast pain, also called mastalgia, has the second-best evidence base and possibly the most consistent results.

Ooi 2020 reviewed 25 studies, including 17 randomized trials. The typical dose was 20 to 40 mg per day for 3 months. A conservative meta-analysis of 6 studies covering 718 women found a standardized mean difference of 0.67 (95% CI 0.5 to 0.85) in favor of vitex. Seven trials found it noninferior to dopamine agonists, NSAIDs, SSRIs, or hormonal contraceptives. Risk of bias was often unclear.

A noninferiority finding is not the same as equal in practice, so do not read that as a head-to-head win. Still, the direction is consistent, the dose range is wider than for PMS, and a 2005 review by Roemheld-Hamm also reports evidence for cyclical breast discomfort.

One practical note: new, one-sided, or persistent breast pain deserves a clinician's look, not a supplement experiment.

PMDD: limited evidence, not a substitute for treatment

PMDD is not simply severe PMS, and the vitex evidence here is thinner.

Atmaca 2003 randomized 41 women with PMDD to fluoxetine or vitex for two months. Response rates were 68.4% on fluoxetine and 57.9% on vitex, a difference that was not statistically significant. In that trial, fluoxetine was associated with better scores on psychological symptoms, while vitex was associated with better scores on physical symptoms. The trial was small, single-blind, and rater-blinded.

A non-significant difference in a 41-woman trial is not a win. It is an absence of a detected difference, in a study too small to settle the question. A 2013 review by van Die and colleagues found PMDD results mixed: one trial equivalent to fluoxetine, another worse.

Do not stop or change a prescribed treatment to try vitex. If you have PMDD, that conversation belongs with your clinician. Our guide to PMDD supplements explains why the treatment evidence looks different from the PMS evidence.

Cycle regularity, ovulation, and fertility: weak and confounded

This is the claim with the widest gap between marketing and data.

Roemheld-Hamm 2005 reviewed the literature and concluded that data for menstrual irregularities and fertility were weak. van Die 2013 identified 13 randomized trials and included 12: eight in PMS, two in PMDD, and two in latent hyperprolactinemia. None of the included trials was a fertility trial. The two hyperprolactinemia trials were positive but small.

The pregnancy claim usually traces back to Westphal 2006, a trial of a combination product called FertilityBlend. It contained chasteberry, green tea, L-arginine, vitamins, and minerals. After three months, 26% of the supplement group were pregnant versus 10% of the placebo group (p=0.01). That result belongs to the combination and cannot be attributed to vitex alone. It also does not show that vitex improves fertility.

If irregular cycles are your main concern, our guide to supplements for irregular periods looks at the wider set of options. For painful periods linked to endometriosis, our guide to supplements for endometriosis covers that separate topic.

If you have PCOS or you are using fertility medication, talk to your clinician before adding any herbal supplement. Vitex is not a treatment for PCOS, and it has not been established as safe alongside fertility drugs.

Menopause: mixed and small

Menopause content about vitex is plentiful. The trial support is not.

Naseri 2019 randomized 52 women to vitex or placebo for 8 weeks and measured symptoms on the Greene Scale. Total menopausal scores, anxiety scores, and vasomotor scores improved compared with placebo. Somatic, depression, and sexual dysfunction scores did not. The trial was small and short.

van Die 2009 tested a combination of St John's wort and vitex in 100 perimenopausal or postmenopausal women for 16 weeks. The combination did not significantly improve symptoms versus placebo. Laakmann 2012 reviewed the climacteric literature and found vitex monotherapy no better than placebo.

One negative trial, one negative review, and one small positive trial are not a foundation for a menopause claim. If hot flashes are your main concern, our guides to hot flashes and night sweats and hormone balance supplements for menopause cover better-supported options.

Acne, libido, lactation, and other claims

Some vitex claims have no human evidence behind them at all. It is worth saying that plainly.

  • Acne. No controlled human trials support vitex for acne. MSKCC lists acne among reported side effects, which is the opposite direction from a benefit claim.
  • Libido. No human trials. The idea comes from the plant's old reputation, not from measured outcomes.
  • Lactation. Dugoua 2008 found poor evidence in lactation and conflicting theoretical opinions. LactMed advises avoiding chasteberry during breastfeeding because of possible milk suppression. It is not a lactation aid.
  • "Hormone balancing." Hormones are not a single dial. No trial measured "balance." Trials measured symptom scores, and the results vary by symptom.
  • Progesterone. No trial cited here measured a progesterone increase from vitex. The proposed mechanism centers on dopamine and prolactin rather than progesterone.

The pattern is consistent: the claims with the least evidence attract the most confident marketing.

If your interest is estrogen metabolism rather than vitex itself, that is a different pathway. Our guide to DIM and estrogen metabolism covers what the evidence supports there.

Dose and timeline: what three cycles looks like

The studied protocol is simple, and it is narrower than most labels suggest.

  • Studied dose: 20 mg of Ze 440 once daily, or one tablet of BNO 1095 once daily.
  • Duration: three cycles, which is roughly three months.
  • Cyclic breast pain: 20 to 40 mg per day for three months in the reviewed trials.
  • Timing: take it at the same time each day so the trial period is consistent.
Vitex trial timeline from baseline through cycle 1, cycle 2, cycle 3, to decide, with a symptom diary.
The trials measured change over three cycles. A baseline cycle makes the comparison possible.

Three cycles is the minimum fair test because that is what the trials measured. Do not increase the dose beyond what was studied in the hope of a bigger effect. The one dose-response trial found 30 mg no better than 20 mg.

What to track for three cycles

  1. Your top three symptoms, rated 0 to 10 each day.
  2. Cycle dates and length, so you can compare like with like.
  3. Breast pain, including days affected, severity, and whether it is one side or both.
  4. Mood and irritability, especially the week before your period.
  5. Sleep, both hours and quality.
  6. Skin, headaches, and digestion, so side effects do not get mistaken for progress.
  7. Anything else you add or change, including medicines and other supplements.

Record one full cycle before you start. That baseline is what makes the comparison possible. Without a baseline, you cannot tell a real change from a good month.

The decision point at the end of cycle 3

Compare averages, not single days. If your top symptoms have not meaningfully changed, stop. If they have improved partly, decide with your clinician whether continuing is worth it. If side effects appear, stop sooner. Do not stay on it indefinitely "just to see."

A concrete example helps. If your premenstrual mood rating averaged 7 out of 10 at baseline and averages 6 across cycle 3, that is noise. If it averages 3, that is the kind of shift the trials were measuring. The number matters less than the size of the change and whether it shows up in more than one cycle.

Safety, side effects, and interactions

Vitex is generally well tolerated in short-term trials. That is not the same as risk free, and the groups who should avoid it are specific.

Common side effects

Reported effects include nausea, headache, digestive upset, menstrual changes, acne, itching, and rash. LactMed describes them as usually mild and reversible; NCCIH and MSKCC list the same effects. Berger 2000 recorded 37 adverse events across 20 patients, none serious. Schellenberg 2001 recorded seven mild events, none leading to discontinuation.

If something new appears, stop and note when it started. Reported effects are usually mild and reversible. A spreading rash, swelling, trouble breathing, or severe abdominal pain needs medical care rather than a wait-and-see approach.

Interactions

MSKCC lists interactions with:

  • Antipsychotics and phenothiazines
  • Antiparkinson drugs
  • Hormonal medicines, including oral contraceptives
  • CYP2C19 and CYP3A4 substrates

The clinical significance of the enzyme interaction is uncertain. The dopamine interactions follow from the proposed mechanism, so they are worth taking seriously. If you take a medicine that acts on dopamine, or any hormonal medicine, ask a pharmacist before adding vitex.

Who should not take it

  • Anyone who is pregnant
  • Anyone who is breastfeeding
  • Anyone with a hormone-sensitive condition or a hormone-sensitive cancer
  • Anyone taking antipsychotics, phenothiazines, or dopamine agonists for Parkinson's disease without clinician or pharmacist clearance
  • Anyone taking hormonal medicines or oral contraceptives without clinician clearance
  • Anyone with PCOS or using fertility treatment, until they have asked their clinician
Checklist card of who should skip vitex: pregnancy, breastfeeding, hormone-sensitive cancer, dopamine drugs, hormonal meds.
These groups should not start vitex without clinician guidance.

None of this is meant to scare you off. It is meant to put vitex in the right category: a herb with real pharmacology, not a free pass because it is sold without a prescription.

The bottom line

Vitex is neither a hype story nor a nothing. It sits in the middle, with moderate evidence for PMS and cyclic breast pain, limited evidence for PMDD, and weak or absent evidence almost everywhere else.

Three habits will serve you better than any ranking of brands:

  • Look for the extract, not the milligram count. Ze 440 and BNO 1095 are the preparations behind most of the trial evidence. A different extract at a larger milligram number is still a different extract.
  • Give it three cycles and track your baseline. The trials measured change over three cycles, and so should you.
  • Treat it as a supplement with pharmacology. That means checking interactions, avoiding it in pregnancy and breastfeeding, and asking a clinician first if you have PCOS or use fertility medication.

If your expectation is a familiar option with moderate evidence for cyclical symptoms, vitex is reasonable to discuss with your clinician. If your expectation is a hormone reset, the evidence does not support that, and no bottle will deliver it.

What We Recommend

None of the products below is Ze 440 or BNO 1095, so none can be compared milligram for milligram with the trial extracts. The cards are here so you can compare labels on extract identity, standardization, milligrams per capsule, and capsules per day.

  • Integrative Therapeutics, Vitex Extract 60 Veg Capsules delivers 225 mg of chaste tree berry extract standardized to 0.5% agnusides (1 mg) per capsule, and the label suggests 1 capsule twice daily, which gives 450 mg of this extract per day. That is a different extract and a different daily amount from the 20 mg Ze 440 tablet. Price: $27.50.
  • Pure Encapsulations, Chaste Tree (Vitex) 60 and 120 Capsules delivers 225 mg of chaste tree fruit extract per capsule at 1 capsule daily, a single-herb option at the lowest entry price here. The label does not name a trial extract. Price: $16.20 for 60 capsules or $29.60 for 120 capsules.
  • Allergy Research Group, DIM Vitex 120 Veg Capsules provides 75 mg of vitex berry extract standardized to 0.5% agnusides per 2 capsules, plus 150 mg BioResponse DIM, 25 mg vitamin B6 as P5P, 50 mg magnesium, and 50 mcg chromium, so it is a combination formula rather than a plain vitex product. Price: $61.19.

References

  1. Csupor D, Lantos T, Hegyi P, et al. Vitex agnus-castus in premenstrual syndrome: A meta-analysis of double-blind randomised controlled trials. Complement Ther Med. 2019;47:102190. doi:10.1016/j.ctim.2019.08.024. PMID 31780016. https://pubmed.ncbi.nlm.nih.gov/31780016/
  2. Verkaik S, Kamperman AM, van Westrhenen R, Schulte PFJ. The treatment of premenstrual syndrome with preparations of Vitex agnus castus: a systematic review and meta-analysis. Am J Obstet Gynecol. 2017;217(2):150-166. doi:10.1016/j.ajog.2017.02.028. PMID 28237870. https://pubmed.ncbi.nlm.nih.gov/28237870/
  3. Cerqueira RO, Frey BN, Leclerc E, Brietzke E. Vitex agnus castus for premenstrual syndrome and premenstrual dysphoric disorder: a systematic review. Arch Womens Ment Health. 2017;20(6):713-719. doi:10.1007/s00737-017-0791-0. PMID 29063202. https://pubmed.ncbi.nlm.nih.gov/29063202/
  4. Schellenberg R. Treatment for the premenstrual syndrome with agnus castus fruit extract: prospective, randomised, placebo controlled study. BMJ. 2001;322(7279):134-137. doi:10.1136/bmj.322.7279.134. PMID 11159568. https://pubmed.ncbi.nlm.nih.gov/11159568/
  5. Schellenberg R, Zimmermann C, Drewe J, Hoexter G, Zahner C. Dose-dependent efficacy of the Vitex agnus castus extract Ze 440 in patients suffering from premenstrual syndrome. Phytomedicine. 2012;19(14):1325-1331. doi:10.1016/j.phymed.2012.08.006. PMID 23022391. https://pubmed.ncbi.nlm.nih.gov/23022391/
  6. Berger D, Schaffner W, Schrader E, Meier B, Brattstrom A. Efficacy of Vitex agnus castus L. extract Ze 440 in patients with pre-menstrual syndrome (PMS). Arch Gynecol Obstet. 2000;264(3):150-153. doi:10.1007/s004040000123. PMID 11129515. https://pubmed.ncbi.nlm.nih.gov/11129515/
  7. Ma L, Lin S, Chen R, Wang X. Treatment of moderate to severe premenstrual syndrome with Vitex agnus castus (BNO 1095) in Chinese women. Gynecol Endocrinol. 2010;26(8):612-616. doi:10.3109/09513591003632126. PMID 20334585. https://pubmed.ncbi.nlm.nih.gov/20334585/
  8. Ma L, Lin S, Chen R, Zhang Y, Chen F, Wang X. Evaluating therapeutic effect in symptoms of moderate-to-severe premenstrual syndrome with Vitex agnus castus (BNO 1095) in Chinese women. Aust N Z J Obstet Gynaecol. 2010;50(2):189-193. doi:10.1111/j.1479-828X.2010.01137.x. PMID 20522079. https://pubmed.ncbi.nlm.nih.gov/20522079/
  9. Atmaca M, Kumru S, Tezcan E. Fluoxetine versus Vitex agnus castus extract in the treatment of premenstrual dysphoric disorder. Hum Psychopharmacol. 2003;18(3):191-195. doi:10.1002/hup.470. PMID 12672170. https://pubmed.ncbi.nlm.nih.gov/12672170/
  10. van Die MD, Burger HG, Teede HJ, Bone KM. Vitex agnus-castus extracts for female reproductive disorders: a systematic review of clinical trials. Planta Med. 2013;79(7):562-575. doi:10.1055/s-0032-1327831. PMID 23136064. https://pubmed.ncbi.nlm.nih.gov/23136064/
  11. Ooi SL, Watts S, McClean R, Pak SC. Vitex agnus-castus for the treatment of cyclic mastalgia: a systematic review and meta-analysis. J Womens Health (Larchmt). 2020;29(2):262-278. doi:10.1089/jwh.2019.7770. PMID 31464546. https://pubmed.ncbi.nlm.nih.gov/31464546/
  12. Naseri R, Farnia V, Yazdchi K, Alikhani M, Basanj B, Salemi S. Comparison of Vitex agnus-castus extracts with placebo in reducing menopausal symptoms: a randomized double-blind study. Korean J Fam Med. 2019;40(6):362-367. doi:10.4082/kjfm.18.0067. PMID 31067851. https://pubmed.ncbi.nlm.nih.gov/31067851/
  13. van Die MD, Burger HG, Bone KM, Cohen MM, Teede HJ. Hypericum perforatum with Vitex agnus-castus in menopausal symptoms: a randomized, controlled trial. Menopause. 2009;16(1):156-163. doi:10.1097/gme.0b013e31817fa9e0. PMID 18791483. https://pubmed.ncbi.nlm.nih.gov/18791483/
  14. Laakmann E, Grajecki D, Doege K, zu Eulenburg C, Buhling KJ. Efficacy of Cimicifuga racemosa, Hypericum perforatum and Agnus castus in the treatment of climacteric complaints: a systematic review. Gynecol Endocrinol. 2012;28(9):703-709. doi:10.3109/09513590.2011.650772. PMID 22385322. https://pubmed.ncbi.nlm.nih.gov/22385322/
  15. Westphal LM, Polan ML, Trant AS. Double-blind, placebo-controlled study of Fertilityblend: a nutritional supplement for improving fertility in women. Clin Exp Obstet Gynecol. 2006;33(4):205-208. PMID 17211965. https://pubmed.ncbi.nlm.nih.gov/17211965/
  16. Roemheld-Hamm B. Chasteberry. Am Fam Physician. 2005;72(5):821-824. PMID 16156340. https://pubmed.ncbi.nlm.nih.gov/16156340/
  17. Puglia LT, Lowry J, Tamagno G. Vitex agnus castus effects on hyperprolactinaemia. Front Endocrinol (Lausanne). 2023;14:1269781. doi:10.3389/fendo.2023.1269781. PMID 38075075. https://pubmed.ncbi.nlm.nih.gov/38075075/
  18. Wuttke W, Jarry H, Christoffel V, Spengler B, Seidlova-Wuttke D. Chaste tree (Vitex agnus-castus): pharmacology and clinical indications. Phytomedicine. 2003;10(4):348-357. doi:10.1078/094471103322004866. PMID 12809367. https://pubmed.ncbi.nlm.nih.gov/12809367/
  19. Dugoua JJ, Seely D, Perri D, Koren G, Mills E. Safety and efficacy of chastetree (Vitex agnus-castus) during pregnancy and lactation. Can J Clin Pharmacol. 2008;15(1):e74-e79. PMID 18204102. https://pubmed.ncbi.nlm.nih.gov/18204102/
  20. National Center for Complementary and Integrative Health. Chasteberry. NCCIH. https://www.nccih.nih.gov/health/chasteberry
  21. Memorial Sloan Kettering Cancer Center. Chasteberry. Updated September 26, 2023. https://www.mskcc.org/cancer-care/integrative-medicine/herbs/chasteberry
  22. Drugs and Lactation Database (LactMed). Chasteberry. National Institute of Child Health and Human Development. Updated November 15, 2024. PMID 30000866. https://pubmed.ncbi.nlm.nih.gov/30000866/
  23. Erkert AK. Case Series: Real-Life Experience with Vitex Agnus-Castus Extract Ze 440 Medication in Adolescents. Complement Med Res. 2026. doi:10.1159/000553039. PMID 42424191. https://pubmed.ncbi.nlm.nih.gov/42424191/

Frequently asked questions

How much vitex should I take?

The trials used 20 mg of Ze 440 or one tablet of BNO 1095 once daily for three cycles. Cyclic breast pain trials used 20 to 40 mg per day for three months. A milligram number on a different extract does not translate. Check the extract identity, the standardization, and how many capsules make up a daily dose before comparing.

How long does vitex take to work?

Trials measured results after three cycles, so three months is the fair test. Early improvement is hard to separate from a good month. Track a baseline cycle first, then compare cycle averages rather than single days. If nothing changes after three cycles, stop.

Is vitex better for PMS or PMDD?

PMS has the stronger evidence. A 2019 meta-analysis of three double-blind trials found that women taking vitex were 2.57 times more likely to have a symptom response, though the review could use only a fraction of published trials. PMDD has one small comparison with fluoxetine and mixed results across reviews. Vitex is not a substitute for PMDD treatment.

Does vitex raise progesterone?

No trial cited here measured a progesterone increase from vitex. The proposed mechanism is dopamine activity in the pituitary and a possible effect on prolactin. Progesterone claims usually come from laboratory work or theory. If a page states it as fact, ask which human trial measured it.

Is vitex safe?

Short-term use is generally well tolerated. Reported effects include nausea, headache, digestive upset, menstrual changes, acne, itching, and rash, usually mild and reversible. Avoid it in pregnancy and breastfeeding, with hormone-sensitive conditions or cancers, and alongside certain medicines. Talk to a pharmacist or clinician before starting.

Can I take vitex with birth control or other medication?

Ask first. Vitex is listed as interacting with hormonal medicines and oral contraceptives, antipsychotics and phenothiazines, antiparkinson drugs, and CYP2C19 or CYP3A4 substrates. The real-world size of the enzyme interaction is uncertain. Your pharmacist can check your full list in minutes.

Can I take vitex while pregnant or breastfeeding?

No. Pregnancy and breastfeeding are both listed as reasons to avoid it. Evidence in these groups is poor, and there is a theoretical concern about milk suppression. If you are trying to conceive, treat vitex as something to discuss with your clinician rather than something to start on your own.

Does vitex help PCOS or fertility?

The data are weak and confounded. A 2005 review called the fertility data weak, and a 2006 pregnancy result came from a combination product that included chasteberry, so vitex alone cannot take the credit. If you have PCOS or use fertility medication, talk to your clinician before adding any herbal supplement.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.